Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

MDedge Cardiocast

Conteúdo fornecido por MDedge. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por MDedge ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.

4+ y ago 8:42

MP3•Home de episódios

ISCHEMIA trial hailed as practice changing

The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.

* * *

Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019

* * *

DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics

Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes.

The TWILIGHT of aspirin post-PCI for ACS?

Patients do better post-PCI for non-ST-elevation ACS with ticagrelor monotherapy

Weaknesses exposed in valsartan recall

ED visits for hypertension in month after the 2018 recall spiked 55%

* * *

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgeTweets

87 episódios

#Science #Medicine #Cardiology #Cardiologynews #Biology #Fitness #MDedge #Cardiologists